Celldex Reports Wider Q1 Loss, Announces $345M Offering to Fund Pipeline Through 2028

summarizeSummary

Celldex Therapeutics reported a wider Q1 2026 net loss and announced the completion of a $345 million public offering in April, which is expected to fund operations through 2028 and advance its clinical pipeline.

check_boxKey Events

• Q1 2026 Financial Results

  The company reported a net loss of $78.7 million, or ($1.18) per share, for the first quarter of 2026, compared to a net loss of $53.8 million, or ($0.81) per share, for the comparable period in 2025. R&D expenses increased to $73.0 million from $52.6 million year-over-year.

• Completed $345 Million Public Offering

  In April 2026, Celldex completed an underwritten public offering, issuing 11,896,750 shares of common stock and raising gross proceeds of $345.0 million. This offering significantly increases the share count and provides substantial capital.

• Extended Cash Runway Through 2028

  The net proceeds from the April offering, combined with existing cash, are projected to fund the company's operations and working capital requirements through 2028, providing long-term financial stability.

• Positive Clinical Pipeline Updates

  Enrollment was completed six months ahead of guidance in both Phase 3 chronic spontaneous urticaria (CSU) studies for barzolvolimab, with topline data anticipated in Q4 2026 and a BLA submission planned for 2027. Other studies, including Phase 3 for cold urticaria and symptomatic dermographism, and Phase 2 for prurigo nodularis and atopic dermatitis, are also progressing with data readouts expected in 2026.

auto_awesomeAnalysis

Celldex Therapeutics reported a significant increase in its net loss for Q1 2026 compared to the prior year, driven by higher R&D expenses as it advances its clinical pipeline. Crucially, the company announced the completion of a $345 million public offering in April 2026, which involved issuing approximately 11.9 million shares. This offering, representing a substantial portion of the company's market capitalization and existing shares, is highly dilutive but provides critical funding to extend the cash runway through 2028. The capital raise supports ongoing and upcoming clinical milestones for its lead asset, barzolvolimab, including early completion of Phase 3 CSU enrollment and anticipated topline data in Q4 2026, alongside progress in other pipeline programs. This filing highlights the trade-off between significant dilution and securing long-term financial stability for a clinical-stage biotech.